Larimar Therapeutics, Inc. Common Stock
LRMRLarimar Therapeutics, Inc. is a biotechnology company focused on developing treatments for rare and genetically defined diseases. The company utilizes its proprietary drug delivery platform to develop therapies targeting disorders such as Friedreich's ataxia and other neurodegenerative and metabolic conditions. Founded with an emphasis on innovative approaches to challenging diseases, Larimar aims to improve patient outcomes through novel therapeutic solutions.
Company News
Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics regarding its nomlabofusp drug candidate for Friedreich's Ataxia. The company's stock fell significantly after disclosing serious safety concerns—anaphylaxis in 7 participants in September 2025 and in 10 of 43 patients by June 2026—despite characteri...
Larimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotechnology company, announced the pricing of an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The offering is expected to close on February 27, 2026, with proceeds to be used for development of nomlabofusp and genera...
Larimar Therapeutics priced an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to support development of nomlabofusp for Friedreich's ataxia and for general corporate purposes. The offering is expected to close on February 27, 2026, with J....
DJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.
DJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.
